What is HC Wainwright’s Estimate for XBIO FY2025 Earnings?

Xenetic Biosciences Inc (NASDAQ:XBIO) – Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Xenetic Biosciences in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($3.24) per share for the year, down from their prior forecast of ($0.66). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2026 earnings at ($0.45) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.48) EPS.

Xenetic Biosciences Stock Up 2.0 %

Shares of Xenetic Biosciences stock opened at $3.44 on Monday. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The company’s 50 day moving average is $3.96 and its 200 day moving average is $3.99. The company has a market cap of $5.30 million, a price-to-earnings ratio of -1.29 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.48). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation acquired a new stake in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned about 0.71% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.